Fennec Pharmaceuticals Inc.
FENC
$9.04
$0.364.15%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 33.30M | 30.91M | 47.54M | 49.35M | 48.89M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.30M | 30.91M | 47.54M | 49.35M | 48.89M |
| Cost of Revenue | 3.37M | 3.01M | 3.18M | 3.20M | 2.17M |
| Gross Profit | 29.94M | 27.91M | 44.35M | 46.15M | 46.72M |
| SG&A Expenses | 39.26M | 39.49M | 41.48M | 44.18M | 40.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.98M | 42.90M | 44.97M | 47.66M | 43.02M |
| Operating Income | -9.68M | -11.98M | 2.57M | 1.68M | 5.87M |
| Income Before Tax | -11.67M | -14.07M | -71.00K | -1.13M | 2.74M |
| Income Tax Expenses | 365.00K | 365.00K | 365.00K | -- | -- |
| Earnings from Continuing Operations | -12.04 | -14.44 | -0.44 | -1.13 | 2.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.04M | -14.44M | -436.00K | -1.13M | 2.74M |
| EBIT | -9.68M | -11.98M | 2.57M | 1.68M | 5.87M |
| EBITDA | -9.58M | -11.88M | 3.37M | 4.28M | 9.45M |
| EPS Basic | -0.44 | -0.53 | -0.01 | -0.04 | 0.10 |
| Normalized Basic EPS | -0.26 | -0.32 | 0.00 | -0.02 | 0.06 |
| EPS Diluted | -0.45 | -0.54 | -0.08 | -0.10 | 0.04 |
| Normalized Diluted EPS | -0.26 | -0.32 | -0.04 | -0.06 | 0.02 |
| Average Basic Shares Outstanding | 110.07M | 109.71M | 109.17M | 108.55M | 107.77M |
| Average Diluted Shares Outstanding | 110.07M | 109.71M | 113.26M | 112.64M | 111.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |